Divi’s Laboratories announced a long-term manufacturing and supply agreement with a global pharmaceutical company, focusing on advanced intermediates — a key area of its custom synthesis business.

In a regulatory filing, the company said the deal is international in scope and is expected to make a meaningful contribution to its revenue. While the partner’s identity and financial specifics remain undisclosed due to confidentiality, Divi’s confirmed the deal’s significance.

To support this agreement and future growth, the company plans to invest Rs 650–700 crore in expanding capacity at its existing facilities. The investment will be funded through internal accruals.

Divi’s stated the deal ensures supply reliability for the customer and strengthens its position in the custom synthesis market.

Stocks Insights? Let the Analyst Guide You.

The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!